Search Results Search Sort by RelevanceMost Recent Policy Forum Feb 2022 How Should Tactical Clinicians Help Make Use of Force More Just? David Callaway, MD and Faroukh Mehkri, DO A public health approach to violence is required to help 21st-century policing evolve. AMA J Ethics. 2022;24(2):E133-139. doi: 10.1001/amajethics.2022.133. Policy Forum Feb 2022 How Should Exposure Risk to Tactical Personnel Be Balanced Against Clinical and Ethical Rescue Demand? Mollie V. Williams, MD, MPH and Olaitan Ajisafe, MD, PharmD Chemical, biological, radiological, nuclear, and explosive device mass casualty incidents mean patients require prehospital and hospital care. AMA J Ethics. 2022;24(2):E140-144. doi: 10.1001/amajethics.2022.140. Policy Forum Apr 2019 How Should Engineered Nanomaterials Be Regulated for Public and Environmental Health? David B. Resnik, JD, PhD Minimizing and managing risks of ENMs means considering whether and when existing legal frameworks offer sufficient protection. AMA J Ethics. 2019;21(4):E363-369. doi: 10.1001/amajethics.2019.363. Policy Forum Jul 2016 Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad Jing Luo, MD and Aaron S. Kesselheim, MD, JD, MPH The Trans-Pacific Partnership Agreement could affect low-income patients’ access to medicines in signatory countries by reducing generic competition. AMA J Ethics. 2016;18(7):727-735. doi: 10.1001/journalofethics.2016.18.7.pfor1-1607. Policy Forum Dec 2019 How Should Gene Editing Be Managed by Risk Managers? David Sine, D.Bioethics Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies. AMA J Ethics. 2019;21(12):E1059-1064. doi: 10.1001/amajethics.2019.1059. Policy Forum Aug 2019 Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications? Jordan M. Warchol, MD, MPH In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013. AMA J Ethics. 2019;21(8):E661-667. doi: 10.1001/amajethics.2019.661. Policy Forum Aug 2019 Why Are Biosimilars Not Living up to Their Promise in the US? Mike Z. Zhai, Ameet Sarpatwari, JD, PhD, and Aaron S. Kesselheim, MD, JD, MPH Overall utilization of the few biosimilars currently available to patients has been limited. AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668. Policy Forum Mar 2020 What Should Health Care Organizations Do to Reduce Billing Fraud and Abuse? Katherine Drabiak, JD and Jay Wolfson, DrPH, JD Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions. AMA J Ethics. 2020;22(3):E221-231. doi: 10.1001/amajethics.2020.221. Policy Forum Feb 2022 ¿Cómo deberían los clínicos tácticos ayudar a hacer un uso más justo de la fuerza? David Callaway, MD and Faroukh Mehkri, DO AMA J Ethics. 2022;E133-139. doi: 10.1001/amajethics.2022.133. Policy Forum Feb 2022 ¿Cómo se debería equilibrar el riesgo para el personal táctico con los requerimientos clínicos y ética de rescate? Mollie V. Williams, MD, MPH and Olaitan Ajisafe, MD, PharmD AMA J Ethics. 2022;E140-144. doi: 10.1001/amajethics.2022.140. Pagination Current page 1 Page 2 Page 3 Next page Next › Last page Last »
Policy Forum Feb 2022 How Should Tactical Clinicians Help Make Use of Force More Just? David Callaway, MD and Faroukh Mehkri, DO A public health approach to violence is required to help 21st-century policing evolve. AMA J Ethics. 2022;24(2):E133-139. doi: 10.1001/amajethics.2022.133.
Policy Forum Feb 2022 How Should Exposure Risk to Tactical Personnel Be Balanced Against Clinical and Ethical Rescue Demand? Mollie V. Williams, MD, MPH and Olaitan Ajisafe, MD, PharmD Chemical, biological, radiological, nuclear, and explosive device mass casualty incidents mean patients require prehospital and hospital care. AMA J Ethics. 2022;24(2):E140-144. doi: 10.1001/amajethics.2022.140.
Policy Forum Apr 2019 How Should Engineered Nanomaterials Be Regulated for Public and Environmental Health? David B. Resnik, JD, PhD Minimizing and managing risks of ENMs means considering whether and when existing legal frameworks offer sufficient protection. AMA J Ethics. 2019;21(4):E363-369. doi: 10.1001/amajethics.2019.363.
Policy Forum Jul 2016 Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad Jing Luo, MD and Aaron S. Kesselheim, MD, JD, MPH The Trans-Pacific Partnership Agreement could affect low-income patients’ access to medicines in signatory countries by reducing generic competition. AMA J Ethics. 2016;18(7):727-735. doi: 10.1001/journalofethics.2016.18.7.pfor1-1607.
Policy Forum Dec 2019 How Should Gene Editing Be Managed by Risk Managers? David Sine, D.Bioethics Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies. AMA J Ethics. 2019;21(12):E1059-1064. doi: 10.1001/amajethics.2019.1059.
Policy Forum Aug 2019 Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications? Jordan M. Warchol, MD, MPH In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013. AMA J Ethics. 2019;21(8):E661-667. doi: 10.1001/amajethics.2019.661.
Policy Forum Aug 2019 Why Are Biosimilars Not Living up to Their Promise in the US? Mike Z. Zhai, Ameet Sarpatwari, JD, PhD, and Aaron S. Kesselheim, MD, JD, MPH Overall utilization of the few biosimilars currently available to patients has been limited. AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668.
Policy Forum Mar 2020 What Should Health Care Organizations Do to Reduce Billing Fraud and Abuse? Katherine Drabiak, JD and Jay Wolfson, DrPH, JD Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions. AMA J Ethics. 2020;22(3):E221-231. doi: 10.1001/amajethics.2020.221.
Policy Forum Feb 2022 ¿Cómo deberían los clínicos tácticos ayudar a hacer un uso más justo de la fuerza? David Callaway, MD and Faroukh Mehkri, DO AMA J Ethics. 2022;E133-139. doi: 10.1001/amajethics.2022.133.
Policy Forum Feb 2022 ¿Cómo se debería equilibrar el riesgo para el personal táctico con los requerimientos clínicos y ética de rescate? Mollie V. Williams, MD, MPH and Olaitan Ajisafe, MD, PharmD AMA J Ethics. 2022;E140-144. doi: 10.1001/amajethics.2022.140.